NUVB
Overvalued by 91.9% based on the discounted cash flow analysis.
Market cap | $1.27 Billion |
---|---|
Enterprise Value | $1.23 Billion |
Dividend Yield | $- (-) |
Earnings per Share | $-2.11 |
Beta | 1.49 |
Outstanding Shares | 340,746,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -6.23 |
---|---|
PEG | 7.14 |
Price to Sales | - |
Price to Book Ratio | 3.71 |
Enterprise Value to Revenue | 86.03 |
Enterprise Value to EBIT | -5.74 |
Enterprise Value to Net Income | -7 |
Total Debt to Enterprise | 0.17 |
Debt to Equity | 0.57 |
No data
No data
Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically ...